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282Objective: Despite improved long-term survival after pediatric heart transplantation, perioperative mortality
has remained high. We sought to understand the factors associated with perioperative graft loss after pediatric
heart transplantation.
Methods: The factors associated with primary heart transplant mortality and retransplantation before hospital
discharge in 226 pediatric heart transplant recipients (1995-2010) at a single-center institution were analyzed
using multivariable logistic regression models adjusted for age at surgery and year of surgery.
Results: A total of 26 patients died (n ¼ 21) or underwent retransplantion (n ¼ 5) before hospital discharge
secondary to primary graft failure (n ¼ 10), multisystem organ failure (n ¼ 5), infection (n ¼ 4), rejection
(n ¼ 2), and perioperative complications (n ¼ 5). United Network for Organ Sharing status 1 (vs status 2) at
transplantation was associated with an increased odds of death from noncardiac causes (odd ratio [OR],
4.7; 95% confidence level [CI], 1.2-22.3; P¼ .002). The factors associated with increased odds of perioperative
mortality or retransplant were pre- and post-transplant extracorporeal membrane oxygenation (OR, 5.3; 95%CI,
1.5-18.7; P ¼ .01; and OR, 25.9; 95% CI, 7.0-95.9; P<.001), longer ischemic times (OR, 1.4 per 30 minutes;
95% CI, 1.0-2.0; P ¼ .04), reoperation after transplantation (OR, 3.5; 95% CI, 1.2-10.4; P ¼ .02), and
transplantation before 2002 (OR, 4.5; 95% CI, 1.4-14.9; P ¼ .01), respectively.
Conclusions: The use of extracorporeal membrane oxygenation (both before and after transplantation), a longer
ischemic time, and reoperation were key factors associated with perioperative graft loss, with noncardiac
mortality closely related to United Network for Organ Sharing status at heart transplantation. Knowledge of
the perioperative risk factors and how they affect graft survival will help guide difficult decisions around
eligibility, timing of primary listing, and appropriateness for retransplantation, and potentially affect
long-term survival. (J Thorac Cardiovasc Surg 2014;148:282-9)Pediatric heart transplantation has been a successful
treatment strategy for children with end-stage heart failure,
with long-term success attributed to advances in surgical
techniques and immunosuppression regimens.1 Despite
this, the 1-year mortality has remained high, with most
deaths occurring before hospital discharge.1 The Interna-
tional Society for Heart and Lung Transplantation (ISHLT)
registry and single-center experiences have demonstrated
that improved survival in the perioperative period can
translate into better long-term outcomes.1-3
Registry data from the ISHLT cites the use of extracorpo-
real membrane oxygenation (ECMO), renal dysfunction,
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The Journal of Thoracic and Cardiovascular Surgindividuals, and era of transplantation as important risk fac-
tors for 1-year mortality.1,4 From these known risk factors,
risk prediction models are being developed using known
patient covariates such as congenital heart disease
diagnosis, level of support, and signs of end organ
dysfunction to predict those at high risk of death in the
perioperative period,5,6 with a goal of improving decision
making around the timing of listing, eligibility for
transplantation, and counseling regarding outcomes.
Although comprehensive and widely applicable, registry
data lacks additional details regarding procedural
information, cardiac diagnosis, and center-specific prac-
tices that could also affect the acute postoperative period.
The factors associated with graft loss before hospital
discharge might be disparate from the factors captured in
1-year mortality analyses, warranting in-depth scrutiny,
because a paucity of published data is available in this area.
Given the limited availability of organs, understanding
and using the perioperative risk factors to help risk stratify
patients could aid in decision making, counseling regarding
the prognosis, and, potentially, improve the clinical
outcomes. The purpose of the present study was to
determine the factors associated with perioperativeery c July 2014
Abbreviations and Acronyms
CHD ¼ congenital heart disease
ECMO ¼ extracorporeal membrane oxygenation
ECLS ¼ extracorporeal life support
ISHLT ¼ International Society for Heart and Lung
Transplantation
PRAs ¼ panel reactive antibodies
UNOS ¼ United Network for Organ Sharing
VAD ¼ ventricular assist device
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XMETHODS
All pediatric patients (age<18 years) who had undergone primary heart
transplantation from 1995 to 2010 at the Hospital for Sick Children, were
included in the present study. The patients who had undergone multiorgan
transplantation were excluded. The research ethics board approved the
study protocol, and the requirement for individual patient consent was
waived in the context of a retrospective study design.
Outcome
The primary outcome for the present study was perioperative graft loss,
defined as either retransplantation (regardless of survival status after re-
transplantation) or death before hospital discharge after primary transplan-
tation. This period was selected instead of the traditional 30-day mortality
period to capture the full extent of in-hospital perioperative related graft
loss and resulted in the inclusion of 4 in-hospital deaths that occurred
within days 32 to 60.
Associated Factors
The associated factors were sought from the patients’ demographic data
and pretransplantation clinical history, clinical status while on the
transplant list, surgical parameters, donor information, and early
postoperative management and complications. Patient status at transplanta-
tion was categorized according to the United Network for Organ Sharing
(UNOS) as status 1 or 2.7 Renal failure was defined as the need for renal
replacement therapy or a glomerular filtration rate < 30 mL/min/
1.73 m2. Arrhythmia was defined as an abnormal heart rhythm resulting
in hemodynamic instability or requiring medical and/or electrical
intervention. Bleeding was defined as any amount of blood loss requiring
2 U of red blood cells within a 48-hour period, pulmonary hemorrhage,
cerebral hemorrhage, reoperation for bleeding, or the use of recombinant
factor VIIa. Missing data from a small number of patients before the
availability of electronic records have been indicated in Table 1.
Mean imputation methods were used to adjust for the missing data in the
multivariable regression models.
Statistical Analysis
The data are presented as the mean  standard deviation, median and
25th and 75th percentiles and interquartile range, and frequencies, as
appropriate. Comparisons between the patients who had experienced
perioperative graft loss before hospital discharge and those who had
survived were performed using Student’s t tests (assuming an unequal
variance between the groups) and Fisher’s exact chi-square test. The factors
associated with achieving the primary outcome were first sought in
univariable logistic regression models for all potential factors. Factors
with a univariable P value< .10 were then included in a multivariableThe Journal of Thoracic and Calogistic regression model adjusted for patient age and year of transplanta-
tion, with a backward selection of variables to obtain a final model.
A bootstrap resampling algorithm (500 random subsamples) was used to
determine the reliability of the individual factors included in the final
multivariable logistic regression model. Factor selection in>50% of the
random subsamples was considered the threshold for high reliability in
the present study. The odds ratio (OR) and 95% confidence intervals
(CIs) are reported. All statistical analyses were performed using Statistical
Analysis Systems, version 9.3 (SAS Institute, Cary NC).RESULTS
Mortality and Retransplantation in Perioperative
Period
A total of 226 primary heart transplants were performed
during the study period, with 26 patients forming the periop-
erative graft loss group. During the 15-year study period, 21
patients died (9%) and 5 underwent retransplantion (2%)
before hospital discharge. After heart transplantation, the
causes of perioperative graft loss included primary graft fail-
ure (n ¼ 10), operative complications (n ¼ 4), multisystem
organ failure (n ¼ 5), infection (n ¼ 4), rejection (n ¼ 2),
and postoperative complications (n ¼ 1).
Patient demographic data. Overall, the pediatric heart
transplant recipients who experienced perioperative graft
loss before hospital discharge were not significantly
different from those who survived with respect to the
underlying diagnosis (cardiomyopathy vs congenital heart
disease), age, era, previous cardiac procedures, blood group
ABO compatibility, waitlist status or duration, and donor
variables (Table 1). In addition, panel reactive antibodies
(PRAs) (>10%) and the use of plasma exchange
transfusion at heart transplantation (in accordance with
the institutional protocol for patients with pre-existing
antibodies) were not significantly different between the
graft loss and graft survival groups. A fetal diagnosis was
more common in patients with perioperative graft loss
(23% vs 8%, P¼ .03), and donor Rh factor–positive status
was more prevalent in the graft survival cohort (88% vs
71%, P ¼ .03). The patients with perioperative graft loss
had somewhat similar intensive care unit stays (median,
20 days; interquartile range, 11-36, vs 5 days, interquartile
range, 3-11; P¼ .09) and significantly shorter postoperative
in-hospital stays (median, 19 days; interquartile range,
8-30, vs 21 days, interquartile range, 13-36; P ¼ .003).
Extracorporeal life support. The pretransplant use of
extracorporeal life support (ECLS), such as ECMO and a
ventricular assist device (VAD) was more common in the
perioperative graft loss group than in the graft survival
group (42% vs 18%, P ¼ .007; Table 2). Although
the use of any ECMO run before transplantation was
significantly greater in the graft loss group than in the
survival group (31% vs 12%, P ¼ .02), the use of a
VAD, multiple or combination ECLS runs, and the total
duration of pretransplant ECLS support were not different
between the 2 groups. The use of post-transplant ECMOrdiovascular Surgery c Volume 148, Number 1 283
TABLE 1. Recipient and donor characteristics
Characteristic Mortality or retransplantation (n ¼ 26) Survival (n ¼ 200) P value
Male gender 13 (50) 115 (56) .53
Etiology
Cardiomyopathy 6 (23) 85 (43) .06
Congenital heart disease 19 (73) 113 (56) .14
Other 1 (4) 2 (1) .31
Diagnostic category
Dilated cardiomyopathy 4 (16) 54 (27) .17
Hypertrophic cardiomyopathy 0 (0) 6 (3) 1.00
Restrictive cardiomyopathy 0 (0) 15 (8) .23
LV noncompaction cardiomyopathy 0 (0) 2 (1) 1.00
Other cardiomyopathy 2 (8) 8 (4) .32
Complex CHD, not HLHS 8 (31) 58 (29) .82
HLHS 10 (38) 43 (21) .08
Other (LV fibroma/EFE) 1 (4) 2 (1) .31
Noncardiac diagnosis, congenital 1 (4) 25 (13) .33
Any noncardiac abnormalities 4 (15) 37 (19) 1.00
Previous procedures
Any cardiac surgery before HTx 15 (58) 96 (48) .41
Pacemaker/AICD before HTx 1 (4) 24 (12) .32
Listing and HTx
Age at HTx listing (y) .57
Median 0.9 3.3
Interquartile range 0.02-12.4 0.3-12.5
Fetal diagnosis 6 (23) 16 (8) .03
HTx waitlist duration (d) .61
Median 51 35
Interquartile range 9-102 14-92
Year of transplantation .36
1992-1999 11 (42) 61 (31)
2000-2004 8 (31) 59 (30)
2005-2010 7 (27) 80 (40)
UNOS status at listing <.01
1 12 (46) 61 (31)
2 14 (54) 139 (69)
UNOS status at transplantation <.01
1 15 (58) 82 (41)
2 11 (42) 115 (59)
Donor and recipient factors
ABO incompatible 6 (23) 41 (20) .80
PRAs>10% 2/24* (8) 31/187* (17) .38
Exchange transfusion 6/14* (43) 42/121* (35) .57
Donor age (y) .67
Median 4.0 5.0
Interquartile range 0.5-23.0 1.0-15.0
Donor cause of death
Anoxia or hypoxia 6/16* (38) 44/132* (33) .78
Trauma 6/16* (38) 58/132* (44) .79
Positive donor Rh status 17 (71) 153 (88) .03
Data presented as n (%) or median and interquartile range. LV, Left ventricular; CHD, congenital heart disease; HLHS, hypoplastic left heart syndrome; EFE, endocardial
fibroelastosis; HTx, heart transplantation; AICD, automatic implantable cardioverter-defibrillator; UNOS, United Network for Organ Sharing; PRAs, panel reactive antibodies;
ABO, Blood Type A, B, or O. *Missing data for early era patients, sample number specified in the denominator.
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Xsupport was significantly greater in the perioperative graft
loss group (46% vs 5%, P< .001); however, the total
duration of support was not significantly different between
the 2 groups.284 The Journal of Thoracic and Cardiovascular SurgOperative factors. The cardiopulmonary bypass (176 vs
122 minutes, P< .001) and total ischemic (291 vs 218
minutes, P< .01) times were significantly longer for the
patients with perioperative graft loss. In the perioperativeery c July 2014
TABLE 2. Surgical and ECLS characteristics
Characteristic Mortality or retransplantation (n ¼ 26) Survival (n ¼ 200) P value
Pre-HTx ECLS
Pre-HTx ECLS 8 (31) 39 (20) .21
Single ECMO cycle 6 (23) 20 (10) .09
Single VAD (Berlin) cycle 0 (0) 15 (8) .23
Combination/multiple ECLS cycles 2 (8) 4 (2) .14
Any pre-HTx ECMO 8 (31) 24 (12) .02
Any pre-HTx VAD 1 (4) 17 (9) .70
Total duration of ECLS support before HTx (d) .79
Median 7 10
Interquartile range 4-22 4-19
Operative factors
Cardiopulmonary bypass time (min) <.001
Median 176 122
Interquartile range 152-208 94-155
Total ischemic time (min) .01
Median 291 218
Interquartile range 240-351 174-298
Chest closed in operating room 16 (62) 170 (85) .01
Duration of chest open after HTx (d) .50
Median 11 4
Interquartile range 6-12 2-5
Post-HTx intervention
Any sternal reopening or reoperation 12 (46) 32 (16) <.001
Chest re-exploration for bleeding 4 (15) 9 (5) .05
Chest re-exploration for cardiac dysfunction 5 (19) 12 (6) .03
Wound infection or debridement 1 (4) 2 (1) .31
Interventional catheterization 1/14* (7) 4/123* (3) .42
Post-HTx ECMO
Post-HTx ECMO 12 (46) 9 (5) <.001
Total duration of ECMO support after HTx (d) 5 (2-10) 4 (2-5) .14
Data presented as n (%) or median and interquartile range. ECLS, Extracorporeal life support; HTx, heart transplantation; ECMO, extracorporeal membrane oxygenation;
VAD, ventricular assist device. *Missing data for early era patients; sample number is specified in the denominator.
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Xgraft loss group, more patients left the operating room
without chest closure (38% vs 15%, P ¼ .01); however,
the average interval the chest remained open after
transplantation was not significantly different between the
2 groups (11 vs 4 days; P ¼ .50). Postoperative repeat
interventions were more likely to occur in patients with
perioperative graft loss, including sternal reopening or
reoperation (46% vs 16%, P < .001), re-exploration
for cardiac dysfunction (19% vs 6%, P ¼ .03), and
re-exploration for bleeding (15% vs 5%, P ¼ .05).
UNOS status. Perioperative graft loss (death or
retransplantation) was examined in 3 categories: all-cause
(n ¼ 26), cardiac (n ¼ 13), and noncardiac (n ¼ 13;
Table 3). In our cohort, the UNOS status at listing was an
important factor associated with noncardiac-relatedTABLE 3. Odds ratios for UNOS status and perioperative graft loss in pe
Perioperative graft loss* All-cause OR (95% CI); P value Ca
UNOS status 1 vs 2 at listing 1.9 (0.8-4.8); .12
UNOS status 1 vs 2 at HTx 1.9 (0.8-4.7); .14
UNOS, United Network for Organ Sharing; HTx, heart transplantation; OR, odds rat
retransplantation (n ¼ 26); noncardiac graft loss did not include retransplantation (n ¼ 21
The Journal of Thoracic and Caperioperative graft loss. Of the 73 patients listed as UNOS
status 1, 12 (16%) experienced the study primary outcome
(cause of graft loss was noncardiac, n ¼ 9, and cardiac,
n ¼ 3). Of the 153 patients listed as UNOS status 2, 14
(9%) experienced the study primary outcome (cause of
graft loss was noncardiac, n ¼ 4, and cardiac, n ¼ 10).
The calculated OR for perioperative graft loss between
UNOS status 1 and 2 at listing was 1.9 (95% CI, 0.8-4.8;
P ¼ .12) for all-cause graft loss, 0.6 (95% CI, 0.1-2.5;
P ¼ .56) for cardiac mortality, and 5.2 (95% CI, 1.4-21.1;
P ¼ .006) for noncardiac mortality. Similar results were
found for the UNOS status at transplantation. Of the 97 pa-
tients transplanted at UNOS status 1, 15 (15%) experienced
the study primary outcome (cause of graft loss was noncar-
diac, n ¼ 10, and cardiac, n ¼ 5). Of the 126 patients
diatric HTx recipients
rdiac OR (95% CI); P value Noncardiac OR (95% CI); P value
0.6 (0.1-2.5); .56 5.2 (1.4-21.1); .006
0.8 (0.2-2.8); .78 4.7 (1.2-22.3); .002
ios; CI, confidence interval. *All-cause and cardiac graft loss included death or
); see text for numbers of patients listed or transplanted at UNOS status 1 versus 2.
rdiovascular Surgery c Volume 148, Number 1 285
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Xtransplanted at UNOS status 2, 11 (9%) experienced
the study primary outcome (cause of graft loss was non-
cardiac, n ¼ 3, and cardiac, n ¼ 8). The calculated OR
for UNOS status 1 versus 2 at transplantation was 1.9
(95% CI, 0.8-4.7; P ¼ .14) for all-cause graft loss, 0.8
(95% CI, 0.2-2.8; P ¼ .78) for cardiac mortality, and 4.7
(95% CI, 1.2-22.3; P¼ .02) noncardiac mortality (Table 3).Univariable Factors Associated With Perioperative
Mortality or Retransplantation
Donor and recipient factors. The assessment of donor
and recipient factors found that the underlying diagnosis,
previous cardiac surgery, and high PRAs (>10%) were
not associated with increased odds of perioperative graft
loss (Table 4). A fetal diagnosis was associated with
increased odds of perioperative graft loss (OR, 3.5; 95%
CI, 1.2-10.3; P ¼ .02) and donor-positive Rh factor was
found to be protective (OR, 0.3; 95% CI, 0.1-0.9; P¼ .02).
Operative factors. An increased total ischemic time (OR,
1.4 per 30 minutes; 95% CI, 1.0-1.8; P ¼ .02), increased
cardiopulmonary bypass time (OR, 1.5 per 30 minutes;
95% CI, 1.2-2.0; P ¼ .002), leaving the operating roomTABLE 4. Univariable perioperative associated factors
Factor
Univariable
OR (95% CI)
P
value
Donor and recipient factors
Fetal diagnosis 3.6 (1.2-10.4) .02
Donor Rh factor positive 0.3 (0.1-0.9) .02
Perioperative course
Longer time to first extubation 1.0 per d (0.99-1.05) .07
Longer time intubated after HTx 1.0 per d (0.99-1.04) .08
Immunosuppression
RATs vs thymoglobulin or
no induction
3.1 (1.2-7.8) .02
ECLS
Any ECMO pre-HTx* 3.3 (1.3-8.6) .01
Multiple ECLS cycles before HTx 5.3 (0.8-33.4) .08
ECMO after HTx 18.1 (6.4-50.8) .001
Total ECMO support after HTx 1.6/d (1.3-2.1) .001
Operative factors
Total ischemic time 1.4 per 30 min (1.1-1.8) .02
Total CPB time 1.5 per 30 min (1.2-2.0) .002
Use of factor VIIa 4.7 (0.8-28.9) .09
Chest not closed in operating room 3.7 (1.5-9.2) .004
Any sternal reopening 4.4 (1.8-10.6) .001
Post-HTx complications
Arrhythmia 2.7 (0.8-8.7) .10
Cardiac arrest 9.6 (1.2-74.9) .03
Hypotension 7.7 (1.5-39.7) .01
Renal failure 5.7 (1.7-19.5) .005
Cardiac dysfunction 3.4 (0.9-11.5) .05
OR, Odds ratio; CI, confidence interval; HTx, heart transplantation; RATs, rabbit
antithymocyte globulin; ECLS, extracorporeal life support; ECMO, extracorporeal
membrane oxygenation; CPB, cardiopulmonary bypass. *Any ventricular assist
device support before HTx (OR, 0.5; 95% CI, 0.1-4.1; P ¼ .52).
286 The Journal of Thoracic and Cardiovascular Surgwithout chest closure (OR, 3.7; 95% CI, 1.5-9.2;
P ¼ .004), and any reoperation after transplantation
(OR, 4.4; 95% CI, 1.8-10.6; P ¼ .001) were associated
with increased odds of perioperative graft loss. The use of
recombinant factor VIIa was associated with an OR of
4.7, which did not reach statistical significance (95% CI,
0.8-8.7; P ¼ .09) in our small cohort.
Perioperative course. The patients with a longer period to
first extubation (OR, 1.02 per day; 95% CI, 1.00-1.05;
P¼ .07) and longer total duration of mechanical ventilatory
support (OR, 1.02 per day; 95% CI, 1.00-1.04; P¼ .08) had
an increased odds of perioperative graft loss.
Protocol induction therapy using rabbit antithymocyte
globulin (locally manufactured, used before 2002)
compared with thymoglobulin (commercially available
rabbit antithymocyte globulin, from 2002 onward) or
no induction was associated with increased odds of
perioperative graft loss (OR, 3.1; 95% CI, 1.2-7.8;
P ¼ .02).
Extracorporeal life support. The use of ECMO both
before and after transplant was associated with an increased
odds of death or retransplantation in the perioperative
period (OR, 5.3; 95% CI, 1.5-18.9; P ¼ .01; and OR,
22.4; 95% CI, 6.1-82.9; P ¼ .001, respectively). Multiple
ECMO and VAD runs before transplantation was associated
with an OR for periopertative graft loss of 5.3, which did not
reach statistical significance (95% CI, 0.8-33; P ¼ .08).
Finally, the total duration of ECMO support after
transplantation was also associated with an increased odds
of perioperative graft loss (OR, 1.6 per day; P ¼ .001).
The pretransplant use of a VAD was not associated with
an increased odds of death or retransplantation (OR, 0.5;
95% CI, 0.1-4.1; P ¼ .52).
Postoperative complications. Perioperative cardiopulmo-
nary arrest (OR, 9.6; 95% CI, 1.2-74.9; P ¼ .03),
hypotension (OR, 7.7; 95% CI, 1.5-39.7; P ¼ .01), renal
failure (OR, 5.7; 95% CI, 1.7-19.5; P ¼ .005), cardiac
dysfunction (OR, 3.4; 95% CI, 0.9-11.5; P ¼ .05), and
arrhythmia (OR, 2.7; 95% CI, 0.8-8.7; P ¼ .10) were all
associated with an increased odds of perioperative graft
loss on univariable analysis.
Multivariable Factors AssociatedWith Perioperative
Mortality or Retransplantation
In multivariable regression modeling (Table 5), adjusted
for age and year of transplantation, we found that the use of
pre- and post-transplant ECMO was associated with an
increased odds of nongraft survival (OR, 5.3; 95% CI,
1.5-18.7; P ¼ .01; and OR, 25.9; 95% CI, 7.0-95.9;
P< .001, respectively). Longer ischemic times (OR, 1.4
per 30 minutes; 95% CI, 1.0-2.0; P ¼ .04) and any reoper-
ation after transplantation (OR, 3.5; 95% CI, 1.2-10.4;
P ¼ .02) were also associated factors. Transplantation
before 2002 (ie, change in induction with rabbitery c July 2014
TABLE 5. Multivariable perioperative risk factors adjusted for year and age at transplantation (model Wald chi-square statistics, 31.1; P<.001;
c-statistic, 0.864)
Variable Reliability in bootstrap* (%) Multivariable OR (95% CI) P value
Use of ECMO after transplantation 100 25.9 (7.0-95.9) <.001
ECMO before transplantation 75 5.3 (1.5-18.7) .01
Longer ischemic time (per 30 min) 70 1.4 (1.0-2.0) .04
Transplantation before 2002 86 4.5 (1.4-14.9) .01
Any reoperation after transplantationy 74 3.5 (1.2-10.4) .02
OR, Odds ratio; CI, confidence interval; ECMO, extracorporeal membrane oxygenation. *All selected variables met the high reliability threshold of>50% selection in random
subsamples created using the bootstrap bagging algorithm. yOther than wound debridement.
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Xantithymocyte globulin to thymoglobulin or no induction)
was also associated with increased perioperative graft loss
(OR, 4.5; 95% CI, 1.4-14.9; P ¼ .01). Although the
incidence of postoperative complications was significant
on univariable analysis, it was not significant in the
multivariable modeling.
DISCUSSION
Understanding the perioperative risk factors and how
they affect graft survival can help guide difficult decisions
around eligibility, the timing of primary listing, and the
appropriateness for retransplantation and could potentially
affect long-term survival. In the present analysis, we found
that use of ECMO (both before and after transplantation),
longer ischemic times, and reoperation in the postoperative
period were associated with increased odds of graft loss in
the perioperative period. Our study results have highlighted
that perioperative mortality is closely associated with the
UNOS status at heart transplantation and that patient
optimization at heart transplantation could minimize the
risk of noncardiac death after transplantation.
Registry data can provide valuable insight into the risk
factors important for 1-year mortality and can demonstrate
an increased risk of graft loss in the perioperative period.1
Although limited single-center reports examining the risk
factors for perioperative mortality are available,3,8-10
recent studies examining the UNOS database have
developed risk prediction models for early mortality
after pediatric heart transplantation using simple
covariates that can be used across institutions to help
guide the discussions around the prognosis and timing of
listing for heart transplantation.5,6 Given the variation in
center-specific practices and the absence of specific details
regarding the operative and postoperative variables in
registry data, examination of single-center experiences is
complementary.
Congenital heart disease (CHD) is the most common
indication for heart transplantation in infancy and has
been associated with decreased post-transplant survival,
particularly in the first year after transplantation.1 More-
over, the Pediatric Heart Transplant Study data reported
worse 3-month post-transplant survival for children with a
diagnosis of CHD compared with those withThe Journal of Thoracic and Cacardiomyopathy.11 In contrast, single-center studies have
demonstrated increased perioperative mortality after heart
transplantation in association with neonatal age and pulmo-
nary reconstruction.2 Within those with CHD, single
ventricle and Fontan circulations have demonstrated
decreased early post-transplant survival in some studies,
potentially related to an older age at transplantation and pre-
vious operations.11,12 In our cohort, we did not find an
association with perioperative graft loss and the initial
diagnosis requiring heart transplantation. A fetal
diagnosis, which typically represents severe CHD, was
associated with an increased risk of graft loss (univariable
analysis) in our cohort. This could potentially have been
related to factors such as elevated pulmonary vascular
resistance in the neonatal and infant period and/or greater
acuity in patients with failed congenital palliation when
listed for heart transplantation (ie, ECLS bridge to
transplantation).
Single-center reports of perioperative risk factors have
been limited, possibly owing to smaller patient numbers8,9
and a focus on long-term outcomes.10,13 The ISHLT data
have identified renal disease as an important risk factor
for 1-year pediatric heart transplantation survival.1 The
risk factors for perioperative renal failure have included
pre-existing renal disease, the diagnosis of CHD, and the
severity of disease leading to transplantation (ie, long
intensive care unit stay and ECMO use).14,15 On
univariable analysis, we found that postoperative
complications such as renal failure were an important
factor associated with perioperative graft loss. However,
this was not significant on multivariable analysis, possibly
owing to our small cohort. The ISHLT data also identified
high PRAs (>10%) as a risk factor for 1-year survival.1
However, we did not find that PRA levels>10% was a
factor associated with perioperative graft loss in our cohort.
Also, the use of exchange transfusion was not different
between the 2 groups.
Multivariable analysis revealed that any reoperation
(excluding retransplantation and wound debridement) after
the initial heart transplantation was statistically significant
in the perioperative graft loss group. Reoperation after
transplantation likely served as a surrogate for graft
dysfunction and bleeding in the perioperative period.rdiovascular Surgery c Volume 148, Number 1 287
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transplant will be more likely to have comorbidities
related to their pretransplant status such as deconditioning
from prolonged mechanical ventilation and being more
susceptible to nosocomial infections, placing them at
greater risk.16
The ischemic time is an important identified risk factor in
the ISHLT registry database.1 However, single-center
studies have not consistently linked a prolonged ischemic
time with perioperative mortality, with some studies
showing tolerance of extended ischemic times.17-19 In a
recent Pediatric Heart Transplant Study, the donor
ischemic times did not affect overall survival.21 However,
longer ischemic times negatively affected 1-year survival,
particularly in older donor hearts,21 in agreement with
studies showing that an extended ischemia time will be
best tolerated in younger donors.20 In addition, ischemic
times longer than 3.5 hours have been associated with an
increased risk of graft loss within 6 months of transplanta-
tion.22 Moreover, the total donor ischemic time has been
associated with a lower mean arterial blood pressure in
the first 24 hours after heart transplantation, a longer stay
in the intensive care unit, and an increased ventilation
time in pediatric heart transplant recipients.23 In our study,
an increased ischemic time (ie, incremental increases per
30 minutes) was associated with increased perioperative
graft loss on multivariable analysis. This suggests that in
children identified as higher risk transplant candidates, the
anticipated ischemic timewould be an important modifiable
consideration for donor selection.
Approximately 25% of children will be bridged to
transplantation with ECLS.1 Although ECLS plays a
valuable role in bridging critically ill patients to transplanta-
tion,24 it has also been a recognized risk factor for
post-transplant survival in both adults and children.1,25
Currently, most infant heart transplant recipients will be
bridged to transplantation using ECMO, with older
children predominantly supported by VADs.1 In a
retrospective study examining the outcomes for ECMO as
a bridge to transplantation, only one half of the children
supported by ECMO survived to hospital discharge.25 This
was in contrast to the recent results from the Berlin Heart
EXCOR trial, which showed improved waitlist survival
and superior post-transplant results compared with
ECMO.26,27 Post-transplant use of ECLS has been shown
to be a useful strategy for high-risk patients with graft
dysfunction, with an acute requirement for ECMO
postoperatively associated with worse outcomes.28,29 In
our study, both pre- and post-transplant use of ECMO was
associated with an increased risk of perioperative graft
loss. An increasing awareness of the outcomes with ECLS
will aid in the discussions with parents and guide decision
making around the institution of ECLS support, especially
in a high-risk clinical setting. In our cohort, the use of a288 The Journal of Thoracic and Cardiovascular SurgVAD in the preoperative period was not associated with
increased graft loss (Tables 2 and 4). Using a small cohort
from our institution, Jeewa and colleagues30 found that the
use ofVADs had a positive effect on greater survival to trans-
plantation and hospital discharge compared with ECMO. In
addition, the ISHLT data have demonstrated that VAD
outcomes will be equivalent to pediatric heart transplant
recipients not requiring ECLS. These results are in contrast
to the outcomes of recipients bridged using ECMO1 and
are in agreement with previous reports.26,30-32 Although
thromboembolic complications, patient complexity (ie,
oxygenation requirements), and size have limited their
widespread application, studies addressing the effect of
pretransplant VAD use on perioperative graft loss are
warranted. Current risk factor studies will serve as a
benchmark as these interventions become more common.
A recent study that addressed risk stratification and trans-
plant benefit for children listed for heart transplantation in
the United States demonstrated that the children at the
greatest risk of waitlist mortality (top 5%) will have a
decreased transplant benefit, given their increased risk of
post-transplant mortality.33 Single-center studies have also
suggested that the pretransplant status is closely linked to
postoperative mortality in pediatric heart transplant
recipients.14,15,34 Our study has demonstrated that a
higher UNOS status will confer a risk of noncardiac death
after heart transplantation, suggesting that some children
will undergo transplantation when their medical urgency
has affected their potential to benefit from a heart
transplant. Although noncardiac death might be a
consequence of transplantation (ie, complications related
to immunosuppression), these data highlight that the
pretransplant status affects post-transplant morbidity and
mortality. Addressing the risk factors within this continuum
could positively affect the outcomes.
Given the shortage of organs available, understanding
who will most benefit for receiving a heart is critical for
ethical decision making. Also, early identification could
allow for strategies to ensure optimization of the patients
at transplantation (ie, preemptive use of a VAD in the place
of emergency ECMO). Although reports have shown
that listing of status 2 patients requires 4 years of post-
transplant survival to show a potential benefit,35 the predic-
tion of potential high-risk patients who are on a transplant
trajectory will allow for stratification and informed decision
making up to the point of transplantation. The recognition
that pretransplant factors heavily affect perioperative
mortality suggests that increasing our understanding of
the risk factors in the perioperative period will lead to
enhanced transplant benefit and patient survival.
Study Limitations
The present study was a retrospective one reporting
the associated factors for a small cohort across multipleery c July 2014
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Xdecades at our single-center institution, such that center-
specific practices and clinical decision making might have
introduced bias. However, an in-depth analysis of institu-
tional practices can help to refine the perioperative risk fac-
tors by including additional factors not censored in larger
registry databases and could serve as benchmarks as new in-
terventions become more widespread.
CONCLUSIONS
The use of ECMO (both before and after transplantation),
longer ischemic times, and reoperation were the key factors
associated with perioperative graft loss, with noncardiac
mortality closely related to the UNOS status at heart
transplantation. Knowledge of the perioperative risk factors
and how they affect graft survival will help guide difficult
decisions around eligibility, the timing of primary listing,
and the appropriateness for retransplantation and could
potentially affect long-term survival.
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